Department of Pharmacology, Dr. DY Patil Medical College, Navi Mumbai, India.
UConn Health Department of Dermatology, Farmington, Connecticut, USA.
J Cosmet Dermatol. 2023 Feb;22(2):395-401. doi: 10.1111/jocd.15363. Epub 2022 Sep 16.
Dermatomyositis is a rare autoimmune inflammatory condition affecting skin and muscles. The disease can be seen in both adults and children. It can be associated with malignancy. Considering involvement of skin in the disease, many patients consult dermatologists for its treatment. Hence, knowledge about its presentation, complications, prognosis, and treatment is necessary.
The objective of this review article is to provide comprehensive information about treatment of dermatomyositis.
In this review article, we reviewed the published literature on adult and juvenile dermatomyositis to highlight the treatment. Articles published in peer-reviewed journals including reviews, clinical trials, case series, and case reports published in electronic database (MEDLINE/PubMed) through January 2021, cross references of respective articles and trials from clinicaltrials.gov were included for qualitative analysis of the literature.
Treatment options for dermatomyositis include traditional immunosuppressive agents and immunomodulatory therapy. High-dose corticosteroids represent the first line of treatment while other immunosuppressive agents are also used, either in combination with or as an alternative to corticosteroids, after initial treatment failure. Some biological agents have been used for the treatment of dermatomyositis with variable responses.
Although several treatment options are available, several questions remain unanswered about the optimal treatment of dermatomyositis.
皮肌炎是一种罕见的影响皮肤和肌肉的自身免疫性炎症性疾病。该病可发生于成人和儿童。它可能与恶性肿瘤有关。鉴于疾病累及皮肤，许多患者会向皮肤科医生寻求治疗。因此，了解其表现、并发症、预后和治疗方法是必要的。
本文旨在提供皮肌炎治疗的全面信息。
在这篇综述文章中，我们回顾了已发表的关于成人和青少年皮肌炎的文献，以突出治疗方法。纳入了同行评议期刊上发表的文章，包括综述、临床试验、病例系列和电子数据库（MEDLINE/PubMed）中的病例报告，通过 2021 年 1 月的临床试验.gov 交叉引用了各自文章和试验，以对文献进行定性分析。
皮肌炎的治疗选择包括传统的免疫抑制剂和免疫调节疗法。大剂量皮质类固醇是一线治疗药物，而其他免疫抑制剂在初始治疗失败后也被联合或替代皮质类固醇使用。一些生物制剂已被用于治疗皮肌炎，但反应不一。
尽管有几种治疗选择，但关于皮肌炎的最佳治疗方法仍存在一些未解决的问题。
